Lederle's Tri-Immunol case
U.S. Supreme Court declines to consider case in which an Idaho Ninth Circuit Court jury awarded $1.1 mil. to a boy paralyzed after receiving Lederle's diphtheria-tetanus-pertussis vaccine Tri-Immounol in 1979. The firm's petition for a writ of certiorari was denied without comment on March 7. The Supreme Court previously agreed to review another Lederle vaccine injury case, which involves FDA liability for approving Lederle's polio vaccine Orimmune ("The Pink Sheet" Jan. 18, T&G-1).
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.